Literature DB >> 36229905

Knowledge and Attitudes of Indonesian General Practitioners Towards the Isoniazid Preventive Therapy Program in Indonesia.

Wira Winardi1, Widhy Yudistira Nalapraya2, Sarifuddin Sarifuddin3, Samsul Anwar4, Amanda Yufika5, Adityo Wibowo6, Iziddin Fadhil7, Hendra Wahyuni Ms8, Yunita Arliny1, Dewi Behtri Yanifitri1, Teuku Zulfikar1, Harapan Harapan9,10,11.   

Abstract

OBJECTIVES: The Indonesian Ministry of Health launched isoniazid preventive therapy (IPT) in 2016, with general practitioners (GPs) at the frontline of this program. However, the extent to which GPs have internalized this program remains uncertain. The aim of this study was to identify the knowledge and attitudes of GPs towards the IPT program in Indonesia.
METHODS: This study used an online, self-administered questionnaire distributed via e-mail and social messaging services. A logistic regression model was employed to identify the explanatory variables influencing the level of knowledge and attitudes toward IPT among GPs in Indonesia. An empirical analysis was conducted separately for each response variable (knowledge and attitudes).
RESULTS: Of the 418 respondents, 128 (30.6%) had a good knowledge of IPT. Working at a public hospital was the only variable associated with good knowledge, with an adjusted odds ratio (aOR) of 1.69 (95% confidence interval [CI], 1.02 to 2.81). Furthermore, 279 respondents (66.7%) had favorable attitudes toward IPT. In the adjusted logistic regression analysis, good knowledge (aOR, 0.55; 95% CI, 0.34 to 0.89), 1-5 years of work experience (aOR, 2.09; 95% CI, 1.21 to 3.60), and having experienced IPT training (aOR, 0.48; 95% CI, 0.25 to 0.93), were significantly associated with favorable attitudes.
CONCLUSIONS: In general, GPs in Indonesia had favorable attitudes toward IPT. However, their knowledge of IPT was limited. GPs are an essential element of the IPT program in the country, and therefore, adequate information dissemination to improve their understanding is critical for the long-term viability and quality of the IPT program in Indonesia.

Entities:  

Keywords:  General practitioner; Isoniazid; Latent tuberculosis; Tuberculosis

Mesh:

Substances:

Year:  2022        PMID: 36229905      PMCID: PMC9561141          DOI: 10.3961/jpmph.22.248

Source DB:  PubMed          Journal:  J Prev Med Public Health        ISSN: 1975-8375


  24 in total

1.  Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis.

Authors:  Chuan-Chin Huang; Mercedes C Becerra; Roger Calderon; Carmen Contreras; Jerome Galea; Louis Grandjean; Leonid Lecca; Rosa Yataco; Zibiao Zhang; Megan Murray
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

Review 2.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

3.  Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia.

Authors:  H T Ayele; M S M van Mourik; M J M Bonten
Journal:  Int J Tuberc Lung Dis       Date:  2016-10       Impact factor: 2.373

4.  The global burden of tuberculosis: results from the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet Infect Dis       Date:  2017-12-07       Impact factor: 71.421

Review 5.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.

Authors:  Rein M G J Houben; Peter J Dodd
Journal:  PLoS Med       Date:  2016-10-25       Impact factor: 11.069

6.  The potential impact of preventive therapy against tuberculosis in the WHO South-East Asian Region: a modelling approach.

Authors:  Sandip Mandal; Vineet Bhatia; Mukta Sharma; Partha Pratim Mandal; Nimalan Arinaminpathy
Journal:  BMC Med       Date:  2020-07-20       Impact factor: 8.775

7.  Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.

Authors:  Jennifer M Ross; Anani Badje; Molebogeng X Rangaka; A Sarah Walker; Adrienne E Shapiro; Katherine K Thomas; Xavier Anglaret; Serge Eholie; Delphine Gabillard; Andrew Boulle; Gary Maartens; Robert J Wilkinson; Nathan Ford; Jonathan E Golub; Brian G Williams; Ruanne V Barnabas
Journal:  Lancet HIV       Date:  2021-01       Impact factor: 12.767

8.  Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public-Private Collaboration.

Authors:  Asik Surya; Budiarti Setyaningsih; Helmi Suryani Nasution; Cicilia Gita Parwati; Yullita E Yuzwar; Mike Osberg; Christy L Hanson; Aaron Hymoff; Pia Mingkwan; Julia Makayova; Agnes Gebhard; Wiendra Waworuntu
Journal:  J Infect Dis       Date:  2017-11-06       Impact factor: 5.226

9.  Global Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2018.

Authors:  Adam MacNeil; Philippe Glaziou; Charalambos Sismanidis; Anand Date; Susan Maloney; Katherine Floyd
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-03-20       Impact factor: 17.586

10.  Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts.

Authors:  Jeremiah Chakaya; Mishal Khan; Francine Ntoumi; Eleni Aklillu; Razia Fatima; Peter Mwaba; Nathan Kapata; Sayoki Mfinanga; Seyed Ehtesham Hasnain; Patrick D M C Katoto; André N H Bulabula; Nadia A Sam-Agudu; Jean B Nachega; Simon Tiberi; Timothy D McHugh; Ibrahim Abubakar; Alimuddin Zumla
Journal:  Int J Infect Dis       Date:  2021-03-11       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.